5 years 1.17
Extreme 1.17
4.82
10 years 1.17
Extreme 1.17
43.2
Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 56 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.28M
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+4.87%+55.97% 51.01B
+1.56%+1.17%+5.15%+33.38% 48.1B
+0.39%+0.65%+28.02%+30.24% 42.78B
+0.87%-8.17%+298.53%+645.03% 40.67B
+1.24%-1.01%+5.56%+105.14% 40.3B
-2.13%-1.64%+7.51%+50.31% 30.59B
-0.46%-1.28%+31.47%+19.93% 28.16B
+5.32%+0.06%-7.20%-11.30% 24.36B
Average +0.74%-2.66%+45.97%+112.35% 41.84B
Weighted average by Cap. +0.56%-2.94%+47.30%+116.51%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14